Orforglipron Weight Loss: What the ATTAIN Phase 3 Trials Showed

By DoseGauge Editorial · Updated 2026-06-13 · 7 min read

In ATTAIN-1, adults with obesity or overweight but without type 2 diabetes lost an average of about 11.2 percent of their body weight at the top trial dose (36 mg) over 72 weeks, using the treatment-regimen estimand, which was the trial's primary analysis. That figure comes from a specific trial dose range (6 mg, 12 mg, and 36 mg) that differs from the doses in the approved Foundayo label (0.8 to 17.2 mg daily). A trial average is also not a prediction for any one person. This page explains what the phase 3 data showed, what it does not tell you, and how the trial design connects to the approved product.

What ATTAIN-1 showed

ATTAIN-1 was a phase 3, randomized, double-blind, placebo-controlled trial in 3,127 adults with obesity (BMI 30 or above) or overweight (BMI 27 or above with at least one weight-related condition) but without type 2 diabetes. Participants received once-daily oral orforglipron at 6 mg, 12 mg, or 36 mg, or placebo, as an adjunct to lifestyle modification, for 72 weeks.

The primary outcome was mean percentage change in body weight from baseline using the treatment-regimen estimand, which accounts for all randomized participants regardless of whether they stayed on treatment.

Results at 72 weeks:

All active doses showed statistically significant reductions versus placebo (p less than 0.001). The trial was published in the New England Journal of Medicine in 2025 (PMID 40960239).

The most common side effects were gastrointestinal: nausea, diarrhea, and vomiting. These were mostly mild to moderate in severity and occurred more often during the titration period. The monthly titration schedule in the approved label is structured specifically to ease this side effect burden over time.

ATTAIN-2 (type 2 diabetes)

ATTAIN-2 enrolled a different population: 1,613 adults with obesity or overweight and type 2 diabetes (HbA1c between 7 and 10%), across 136 sites in ten countries. The trial ran for 72 weeks with the same dose arms (6 mg, 12 mg, 36 mg) and the same treatment-regimen estimand as primary analysis. It was published in The Lancet in 2025 (PMID 41275875).

Results at 72 weeks:

The treatment difference at 36 mg versus placebo was -7.1 percentage points (95% CI -8.2 to -6.1; p less than 0.0001). All prespecified cardiometabolic secondary endpoints, including HbA1c, improved significantly with orforglipron versus placebo. The safety profile in ATTAIN-2 was consistent with ATTAIN-1: gastrointestinal effects were the most common adverse events.

The ATTAIN-2 weight-loss figures are somewhat lower than ATTAIN-1 figures at the same doses. This is typical in GLP-1 trials: people with type 2 diabetes tend to lose less weight on average than those without diabetes, for reasons that are not fully understood but may relate to the underlying disease and concurrent medications.

Trial doses vs the approved label: an important distinction

The ATTAIN trials studied 6 mg, 12 mg, and 36 mg doses of orforglipron. The FDA-approved Foundayo label uses a different titration schedule, starting at 0.8 mg daily and stepping up through six strength levels to a maximum of 17.2 mg daily. The maximum approved maintenance dose (17.2 mg) is substantially lower than the highest trial dose (36 mg).

This distinction matters for interpreting the trial data. An 11.2% average weight loss at 36 mg in ATTAIN-1 is not the expected result of the approved 0.8 to 17.2 mg label schedule. The two dose regimens are different. The FDA approved the product based on the full data package, including the benefit-risk profile at the doses on the label.

For the full breakdown of the approved titration schedule and what each strength looks like in milligrams per day, see the orforglipron dosing schedule.

Setting expectations: averages, time course, and tolerability

A few things are worth understanding before reading any trial weight-loss figure.

Trial averages include everyone, including non-responders. The mean weight loss in a trial includes participants who lost very little and those who lost much more. Some people in ATTAIN-1 lost substantially more than 11.2%, and some lost less. A single average figure does not describe the full distribution of outcomes.

The time course matters. Weight loss in these trials was not immediate. Orforglipron is titrated gradually over several months to reach the maintenance dose, and weight loss continued to accumulate over the 72-week trial period. At the 36 mg dose in ATTAIN-1, plateau had not fully been reached by week 72 for all participants. Early weeks involve titration, not the maintenance dose.

Tolerability and adherence shape real-world outcomes. Gastrointestinal side effects led some trial participants to discontinue. People who are unable to tolerate titration or who do not reach the target dose will have different outcomes than the trial average.

Weight management is a clinical program, not just a drug. Both ATTAIN trials studied orforglipron as an adjunct to lifestyle modification. Participants received counseling on diet and activity. The drug does not replace those components; the evidence is for the combination.

None of the above is a recommendation. It is context for reading a number honestly. The right dose, drug, and weight-management program for any individual is a clinical decision made with a prescriber.

FAQ

How much weight do you lose on orforglipron?

In ATTAIN-1, the phase 3 trial in adults with obesity or overweight but without type 2 diabetes, participants lost an average of about 11.2% of body weight at the top trial dose (36 mg) over 72 weeks, versus about 2.1% with placebo (treatment-regimen estimand; NEJM 2025, PMID 40960239). In ATTAIN-2, the trial in adults with type 2 diabetes, the top trial dose produced about 9.6% mean weight reduction over 72 weeks versus 2.5% placebo (The Lancet 2025, PMID 41275875). These are trial averages at doses (6 mg, 12 mg, 36 mg) that differ from the approved Foundayo label doses (0.8 to 17.2 mg). Individual results vary. An average does not predict what any one person will experience.

How long does it take to lose weight on orforglipron?

The ATTAIN trials ran for 72 weeks (about 17 months). Weight loss accumulated gradually over that period. The approved Foundayo label starts at 0.8 mg daily and titrates upward in monthly steps, so participants spend the early months on lower doses while the body adjusts. Meaningful weight reduction in the trials was observed before 72 weeks, but the full average figure reflects the complete trial duration. Expecting full results in the first few weeks is not consistent with how the drug works.

Is orforglipron as good as the injections?

In their separate phase 3 trials, the injection tirzepatide showed larger average weight loss than orforglipron. The two are not compared head to head; for the specifics and the cited trial figures, see orforglipron vs tirzepatide. Orforglipron's advantage is the pill form: no injections, no food or water restrictions. Whether any drug is right for a person is a clinical decision.

Are these real patient reviews or testimonials?

No. This page summarizes the results of the published phase 3 clinical trials (ATTAIN-1 and ATTAIN-2). It is not a collection of patient testimonials, user reviews, or anecdotal reports. Trial data are averages from randomized controlled studies, not individual outcomes. Individual experiences with orforglipron will vary.

Informational and educational only. Not medical advice. DoseGauge computes from the values you enter and does not recommend a dose. Talk to a licensed clinician before using any peptide or GLP-1 medication.